# IV. 510(k) SUMMARY (As Required by Section 807.92(c)

NOV 2 3 2005

# (A)OWNER'S NAME [807.92(a)(1)]

Owner's Name: Victor J. Santos President   
Company: Natureplex, LLC   
Address: 3791 Airpark Street Memphis, TN 38118   
Phone: (866) 323-0107   
FAX: (901) 323-2088   
Contact Person: Victor J. Santos   
Date Prepared: September 15, 2005

(NAME OF THE DEVICE [807.92(a)(2)]

Trade Name: BE CERTAINTM Home Pregnancy Test   
Common Name: hCG Pregnancy Test   
Classification Name: FDA Product Code: LCX Kit, Test, Pregnancy, hCG, Over-the-Counter

# ()LEGALLY MARKETED DEVICE [807.92(a)(3)]

Substantial equivalence is being claimed with the following legally marketed device: E.P.T. Pregnancy Test (K# 033658).

# DESCRIPTION OF THE DEVICE [807.92(a)(4)]

The BE CERTAINTM Home Pregnancy Test is an hCG assay, comprising of a rapid one-step test, based on an immunochromatographic technology. The test is made up of a membrane with an absorbent pad overlapping a strip of fiber glass paper that is impregnated with a lyophilized colloidal conjugate of gold particles and monoclonal solid phase antibodies to hCG. Other absorbent pads at the end of the assay absorb excess sample fluid. The urine sample is introduced into the device and proceeds through the absorbent pad, then laterally onto a chromatographic membrane. As it contacts the membrane, the sample dissolves the lyophilized conjugate. In a reactive sample, the hCG antigen will attach to the antibodies in the colloidal solution. As the conjugate moves forward on the membrane, anti-hCG monoclonal antibody affixed on the test zone ("T") will bind the hCG-gold conjugate complex, forming a pink line ("T"). All samples will cause a pink colored line to appear in the control zone ("C"). This line is formed by the binding of the polyclonal antibodies (Anti-mouse IgG) affixed onto the control zone to the sample-colloidal gold conjugate. Presence of this line indicates that the test has been carried out correctly. In less than 5 minutes, levels of hCG as low as 25mlU/ml can be detected.

# (E)INTENDED USE OF THE DEVICE [807.92(a)(5)]

The BE CERTAINTM Home Pregnancy Test is intended for the qualitative identification of the elevated level of Human Chorionic Gonadotrophin (hCG) in urine to aid in the determination of pregnancy. It is for over-the-counter consumer use.

# (F) TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE AS COMPARED TO PREDICATE DEVICE [807.92(a)(5)]

The BE CERTAINTM Home Pregnancy Test is substantially equivalent to the E.P.T.® Pregnancy Test [#K033658] based on the following characteristics:

<table><tr><td rowspan=1 colspan=1>ITEM</td><td rowspan=1 colspan=1>BE CERTAINTM HomePregnancy Test</td><td rowspan=1 colspan=1>E.P.T.® Pregnancy Test</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Qualitative identification ofpregnancy hormone i.e.,Human ChorionicGonadotrophin (hCG)</td><td rowspan=1 colspan=1>Qualitative identification ofpregnancy hormone i.e.,Human ChorionicGonadotrophin (hCG)</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Determination of pregnancy</td><td rowspan=1 colspan=1>Determination of pregnancy</td></tr><tr><td rowspan=1 colspan=1>Target Population</td><td rowspan=1 colspan=1>Pregnant women</td><td rowspan=1 colspan=1>Pregnant women</td></tr><tr><td rowspan=1 colspan=1>Where Used</td><td rowspan=1 colspan=1>Home</td><td rowspan=1 colspan=1>Home</td></tr><tr><td rowspan=1 colspan=1>Formats Available</td><td rowspan=1 colspan=1>Casette</td><td rowspan=1 colspan=1>Casette</td></tr><tr><td rowspan=1 colspan=1>Sterility</td><td rowspan=1 colspan=1>Non-sterile</td><td rowspan=1 colspan=1>Non-sterile</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human urine</td><td rowspan=1 colspan=1>Human urine</td></tr><tr><td rowspan=1 colspan=1>Antibodies</td><td rowspan=1 colspan=1>Polyclonal anti-mouseIgGAnti-β-hCG antibody andanti-α hCG monoclonalantibody</td><td rowspan=1 colspan=1>Polyclonal anti-mouseIgGAnti-β-hCG antibody andanti-α hCG monoclonalantibody</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>25 mIU/ml</td><td rowspan=1 colspan=1>25 mIU/ml</td></tr><tr><td rowspan=1 colspan=1>Storage Temperature</td><td rowspan=1 colspan=1>4-30°C</td><td rowspan=1 colspan=1>2-30°C</td></tr><tr><td rowspan=1 colspan=1>Read Time</td><td rowspan=1 colspan=1>3 -5 Minutes</td><td rowspan=1 colspan=1>2-10 Minutes</td></tr></table>

# (G) NON-CLINICAL PERFORMANCE DATA [807.92(b)(1)] AND CONCLUSIONS FROM NON-CLINICAL TESTS [807.92(b)(3)]

# (1) SENSITIVITY/DETECTION LIMIT DATA

To determine the sensitivity/detection limit of the BE CERTAINTM Home Pregnancy Test, the analyte concentration of Human Chorionic Gonadotrophin (hCG) at which $9 5 \%$ of the test results are positive was determined. This was carried out by spiking human urine samples from 30 different non-pregnant male or female subjects with different concentrations of hCG. A total of five different samples at each concentration of hCG was blindly labeled and tested with the BE CERTAINTM Home Pregnancy Test. The results of this study are presented in Table 1 below.

Table 1.   
Sensitivity/Detection Limit Data for the BE CERTAINTM Home Pregnancy Test.   

<table><tr><td rowspan=1 colspan=1>hCG CONCENTRATION</td><td rowspan=1 colspan=1>POSITIVE</td><td rowspan=1 colspan=1>NEGATIVE</td></tr><tr><td rowspan=1 colspan=1>0 mIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td></tr><tr><td rowspan=1 colspan=1>12.5 mIU/ml</td><td rowspan=1 colspan=1>1 of5</td><td rowspan=1 colspan=1>4 of5</td></tr><tr><td rowspan=1 colspan=1>18.75 mIU/ml</td><td rowspan=1 colspan=1>3 of 5</td><td rowspan=1 colspan=1>2 of5</td></tr><tr><td rowspan=1 colspan=1>25 mIU/ml</td><td rowspan=1 colspan=1>5 of 5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=1 colspan=1>50 mIU/ml</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=1 colspan=1>100 mIU/ml</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr></table>

The sensitivity of the BE CERTAINTM Home Pregnancy Test was tested by spiking thirty negative urine samples with varying concentrations of hCG. None of the samples (0%) for 0 mIU/ml of hCG had tested positive. Conversely, 1 out of 5 (20%) and 3 out of 5 (60%) for 12.5 mIU/ml and 18.75 mIU/ml of hCG, respectively, had tested positive. All samples (100%) for 25 mIU/ml, 50 mIU/ml, and 100 mIU/ml had tested positive with the BE CERTAINTM Home Pregnancy Test. The sponsor claims a detection limit of 25 mIU/ml for the BE CERTAINTM Home Pregnancy Test.

# SPECIFICITY DATA INCLUDING LH, FSH, AND TSH

To determine the specificity of the BE CERTAINTM Home Pregnancy Test, in terms of its cross-reactivity with high physiologic concentration of Human Luteinizing Hormone (hLH), Human Follicle Stimulating Hormone (hFSH), and Human Thyroid Stimulating Hormone (hTSH), human urine samples from a total of 45 different normal, non-pregnant females or males were spiked with varying concentration of hLH, hFSH, and hTSH, with or without hCG. The results of this study are presented in Table 2 below.

Table 2. Specificity Data for the BE CERTAINTM Home Pregnancy Test.   

<table><tr><td rowspan=1 colspan=2>HORMONES</td><td rowspan=1 colspan=2>5 mls URINE</td><td rowspan=1 colspan=2>5 mls URINE +10 mIU/ml hCG</td><td rowspan=1 colspan=2>5 mls URINE +50 mIU/ml hCG</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>()</td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td></tr><tr><td rowspan=3 colspan=1>hLH</td><td rowspan=1 colspan=1>100 mIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=1 colspan=1>300 mIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=1 colspan=1>500 mIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=3 colspan=1>hFSH</td><td rowspan=1 colspan=1>100 mIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=1 colspan=1>300 mIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of 5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of 5</td></tr><tr><td rowspan=1 colspan=1>500 mIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=3 colspan=1>hTSH</td><td rowspan=1 colspan=1>750 μIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=1 colspan=1>1,000 μIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of 5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr><tr><td rowspan=1 colspan=1>1,250 μIU/ml</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>5 of5</td><td rowspan=1 colspan=1>0 of5</td></tr></table>

For the human urine samples spiked with hLH, hFSH, and hTSH at varying concentrations, none of the samples (0%) showed a positive reading with the BE

CERTAINTM Home Pregnancy Test. Similarly, for the human urine $+ 1 0 \mathrm { m U / m l }$ hCG samples that were spiked with hLH, hFSH, and hTSH at varying concentrations, none of the samples $( 0 \% )$ showed a positive reading with the BE CERTAINTM Home Pregnancy Test. Conversely, for the human urine $+ 5 0 \mathrm { m I U / m l }$ hCG samples that were spiked with hLH, hFSH, and hTSH at varying concentrations, all samples $( 1 0 0 \% )$ showed a positive reading with the BE CERTAINTM Home Pregnancy Test as would have been expected since the BE CERTAINTM Home Pregnancy Test has been demonstrated to have a detection limit of hCG at $2 5 \mathrm { m I U / m l }$

# (3) INTERFERING SUBSTANCES DATA

To determine the interference by certain exogenous compounds, human urine samples from non-pregnant female or male subjects were spiked with prescription/OTC drugs, chemical analytes, biological analytes, as well as titrated for $\mathfrak { p H }$ , and tested with the BE CERTAIN™ Home Pregnancy Test. The results of the analyte interfering study are presented in Table 3 below.

Table 3: Analyte Interfering Data for the BE CERTAINTM Pregnancy Test.   

<table><tr><td rowspan=2 colspan=1>ANALYTES</td><td rowspan=1 colspan=2>5 mls URINE</td><td rowspan=1 colspan=2>5 mls URINE + 50mIU/ml hCG</td></tr><tr><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>()</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen (20 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Aspirin (20 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Ampicillin (20 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Tetracycline (20 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Caffeine (20 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>0 of3</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid (20 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>0 of3</td></tr><tr><td rowspan=1 colspan=1>Glucose (2000 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Protein (2000 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Albumin (20 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (2 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin (1 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>0 of 3</td></tr><tr><td rowspan=1 colspan=1>Triglyceride (800 mg/dL)</td><td rowspan=1 colspan=1>0 of 3</td><td rowspan=1 colspan=1>3 of 3</td><td rowspan=1 colspan=1>3 of3</td><td rowspan=1 colspan=1>0 of3</td></tr></table>

The results of the $\mathfrak { p H }$ interfering study are presented in Table 4 below.

Table 4: pH Interfering Data for the BE CERTAINTM Pregnancy Test.   

<table><tr><td rowspan=2 colspan=1>pH</td><td rowspan=1 colspan=2>5 mls URINE</td><td rowspan=1 colspan=2>5 mls URINE +50 mIU/ml hCG</td></tr><tr><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td></tr><tr><td rowspan=1 colspan=1>pH 3</td><td rowspan=1 colspan=1>0 of 1</td><td rowspan=1 colspan=1>1 of 1</td><td rowspan=1 colspan=1>1 of 1</td><td rowspan=1 colspan=1>0 of 1</td></tr><tr><td rowspan=1 colspan=1>pH 5</td><td rowspan=1 colspan=1>0 of 1</td><td rowspan=1 colspan=1>1 of 1</td><td rowspan=1 colspan=1>1 of 1</td><td rowspan=1 colspan=1>0 of 1</td></tr><tr><td rowspan=1 colspan=1>pH 7</td><td rowspan=1 colspan=1>0 of 1</td><td rowspan=1 colspan=1>1 of 1</td><td rowspan=1 colspan=1>1 of 1</td><td rowspan=1 colspan=1>0 of 1</td></tr><tr><td rowspan=1 colspan=1>pH 10</td><td rowspan=1 colspan=1>0 of 1</td><td rowspan=1 colspan=1>1 of 1</td><td rowspan=1 colspan=1>1 of 1</td><td rowspan=1 colspan=1>0 of 1</td></tr></table>

No interference was observed by the exogenous compounds tested above, as observed in this study using the BE CERTAINTM Home Pregnancy Test. Further, human urine samples with $\mathtt { p H }$ ranges between 3-10 did not adversely affect the test and produced the expected results.

# (H) CLINICAL PERFORMANCE DATA [807.92(b)(2)] AND CONCLUSIONS FROM CLINICAL TESTS [807.92(b)(3)]

# COMPARISON STUDY USING THE DIP METHOD

Spiked human urine samples from 100 normal, non-pregnant females were tested in order to determine the correlation of the new test, the BE CERTAINTM Pregnancy Test, when used by subjects using a dip method, with that of the BE CERTAINTM Pregnancy Test, l     h  r .T. Pregnancy Test (i.e., the predicate device; previously cleared under 510(k) #K033658) The results of this study are as follows:

Table 5.

Concordance of BE CERTAINTM Home Pregnancy Test (Tested by End User) Compared with BE CERTAINTM Home Pregnancy Test (Tested by Professional User), Both Following a Urine Dip Method.   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>BE CERTAINTM (Prof. User)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>BE CERTAINTM(End User)</td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>61</td></tr><tr><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>cYanmaGntYelowb</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>100</td></tr></table>

Based on the above $2 \mathbf { x } 2$ analysis, the Concordance of the BE CERTAINrM Home Pregnancy Test when tested by the End User and the Professional User is $1 0 0 / 1 0 0 { = } 1 0 0 \%$ with a $9 5 \%$ confidence interval of $9 6 \% - 1 0 0 \%$ The sensitivity of the BE CERTAINTM Home Pregnancy Test is $6 1 / 6 1 = 1 0 0 \%$ , with a $9 5 \%$ confidence interval of $9 4 \% - 1 0 0 \%$ . Finally, the Specificity of the BE CERTAIN™m Home Pregnancy Test is $3 9 / 3 9 = 1 0 0 \%$ with a $9 5 \%$ confidence interval of $9 1 \% - 1 0 0 \%$ .

Table 6.

Concordance of BE CERTAINTM Home Pregnancy Test (Tested by End User) Compared with E.P.T.® Pregnancy Test (Tested by Professional User), Both Following a Urine Dip Method   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>E.P.T.(Prof. User)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>BE CERTAINTM(End User)</td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>61</td></tr><tr><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>100</td></tr></table>

Based on the above $2 \mathbf { x } 2$ analysis, the Concordance of the BE CERTAINrm Home Pregnancy Test when tested by the End User, as compared with the predicate device, the

E.P.T.® Pregnancy Test as tested by the Professional User is $9 9 / 1 0 0 { = } 9 9 \%$ , with a $9 5 \%$ confidence interval of $9 5 \% - 1 0 0 \%$ .The sensitivity of the BE CERTAINTM Home Pregnancy Test is $6 1 / 6 2 { = } 9 8 . 3 \%$ , with a $9 5 \%$ confidence interval of $91 \% - 1 0 0 \%$ Finally, the Specificity of the BE CERTAIN™m Home Pregnancy Test is $3 8 / 3 8 = 1 0 \%$ , with a $9 5 \%$ EY confidence interval of $91 \% - 1 0 0 \%$ .

The above studies show that the BE CERTAINTM Home Pregnancy Test, when used by eiher an end user r a professional user llowing aurinedip method havea sr concordance. Likewise, the BE CERTAINTM Home Pregnancy Test has a strong concordance with the predicate device, the E.P.T.® Pregnancy Test.

# (2) COMPARISON STUDY USING THE URINE DROPSTREAM METHOD

Spiked human urine samples from 50 normal, non-pregnant females were tested in order to determine the correlation of the new test, the BE CERTAINTM Pregnancy Test, when used by subjects using a urine dropstream method, with that of the reference standard, the E.P.T. Pregnancy Test (i.e., the predicate device; previously clearedunder510(k) #K033658). The results of this study are as follows:

Table 7.

Concordance of BE CERTAINTM Home Pregnancy Test (Tested by End User Using a Urine DropStream Method) Compared with E.P.T. Pregnancy Test (Tested by Professional User Using a Urine Dip Method)   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>E.P.T. (Urine Dip)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>BE CERTAIN(Urine Stream)</td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>()</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>50</td></tr></table>

Based on the above $2 \times 2$ analysis, the Concordance of the BE CERTAINTM Home Pregnancy Test when tested by the End User using a urine dropstream method, as compared with the E.P.T.® Pregnancy Test (Tested by Professional User using a Urine Dip Method) is $5 0 / 5 0 { = } 1 0 0 \%$ , with a $9 5 \%$ confidence interval of $9 3 \% - 1 0 0 \%$ The sensitivity of the BE CERTAINTM Home Pregnancy Test is $2 7 / 2 7 = 1 0 0 \%$ , with a $9 5 \%$ E confidence interval of $8 8 \% - 1 0 0 \%$ Finally, the Specificity of the BE CERTAINTM Home Pregnancy Test is $2 3 / 2 3 = 1 0 \%$ , with a $9 5 \%$ confidence interval of $8 6 \% - 1 0 0 \%$ .

As expected, the BE CERTAINTM Pregnancy Test, when tested using the urine dropstream method, had produced equivalent results with that of the dip urine method.

# (l) OTHER INFORMATION [807.92(d)] (1) EXPECTED VALUES

The BE CERTAINTM Home Pregnancy Test is capable of detecting pregnancy by the first day of the missing period and no sooner.

# 2) CALIBRATION

The BE CERTAINTM Home Pregnancy Test is calibrated against the WHO $3 ^ { \mathrm { r d } }$ International Standard for hCG.

# (3) QUALITY CONTROL

The BE CERTAINTM Home Pregnancy Test has built in Quality Control Features. After addition of the urine sample, these colored bands migrate along the membrane at the leading edge of the dye conjugate and are "removed" from the test strip completely.

When the test is complete, the end user will see a pink-purple colored band in the re the est si gativ les nd  i-purpl oe band nd " area n positive samples.The apperance f the CONTROL $\displaystyle ( ^ { 6 6 } { \mathrm { C } } ^ { 5 } )$ band indicates that the test strip is performing properly and serves as a procedural internal control.

# NOV 2 3 2005

Mr. Victor J. Santos President Natureplex, LLC. 3791 Air Park Street Memphis, TN 38118

Re: k051963 Trade/Device Name: BE CERTAIN Pregnancy Test Regulation Number: 21 CFR 862.1155 Regulation Name: Human chorionic gonadotropin (HCG) test system Regulatory Class: Class II Product Code: LCX Dated: November 16, 2005 Received: November 17, 2005

Dear Mr. Santos:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified inaccordance with the provisions of the Federal Food Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/115d5fb7fbbc301c84c6d31e93f46c8bdb06dec8813bd762f8dc085f03992650.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510 (0) Number K051963

Device Name:

BE CERTAIN Pregnancy Test

Indications for Use": The BE CERTAIN Pregnancy Test is intended for the qualitative identification of the elevated level of human Chorionic Gonadotropin (hCG) in urine to aid in the determination of pregnancy. It is for over-thecounter consumer use.

# Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Page 1 of 1

![](images/22c1c8963998fee3ec6b5a168262f737dcba5b6f44fdc87da81a5eaf834fa3a2.jpg)

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K051963